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Results of Extracorporeal Membrane Oxygenation (ECMO) 
Support before Coronary Reperfusion in Cardiogenic Shock 
with Acute Myocardial Infarction
Eui  Suk  Chung,  M.D.*,  Cheong  Lim,  M.D.**,  Hae-Young  Lee,  M.D.***, 
Jin-Ho  Choi,  M.D.****,  Jeong-Sang  Lee,  M.D.*****,  Kay-Hyun  Park,  M.D.**
Background:  Despite aggressive treatment, the mortality rate of cardiogenic shock with acute myocardial infarction 
(AMI) is high. We performed extracorporeal membrane oxygenation (ECMO) prior to coronary reperfusion, and eval-
uated the early clinical results and risk factors. Materials and Methods: From May 2006 to November 2009, we 
reviewed the medical records of 20 patients in cardiogenic shock with AMI (mean age 67.7±11.7 yrs, M : F 14 : 6). 
After initially performing ECMO using the CAPIOX emergency bypass system (EBS
ⓇTerumo, Tokyo, Japan), pa-
tients underwent coronary reperfusion (coronary artery bypass grafting, 13; percutaneous coronary intervention, 7). 
Results: All patients were in a cardiogenic shock state, cardiopulmonary resuscitations (CPR) were performed for 
fourteen patients (mean CPR time 20.8±26.0 min). The mean time from vascular access to the initiation of ECMO 
was 17.2±9.4 min and mean support time was 3.8±4.0 days. Fourteen patients were able to be weaned from 
ECMO and ten patients were discharged (mean admission duration 50.1±31.6 days). Patients survived on average 
476.6±374.6 days of follow-up. Longer CPR and support time, increased cardiac enzyme, lower ejection fraction, 
lower albumin, and major complications were the risk factors of mortality (p＜0.05).  Conclusion: The early applica-
tion of ECMO prior to coronary reperfusion and control of risk factors allowed for good clinical results in cardio-
genic shock with AMI.
Key words: 1. Extracorporeal membrane oxygenation (ECMO) 
2. Coronary reperfusion 
3. Acute myocardial infarction 
4. Cardiogenic shock
INTRODUCTION
The  mortality  rate  of  cardiogenic  shock  due  to  acute  my-
ocardial infarction (AMI) is as high as 60∼80% and may be 
higher  without  aggressive  treatment.  Besides  the  classical 
medical  treatment,  circulatory  supportive  devices  such  as  the 
Intra Aortic Balloon Pump (IABP) and Ventricular Assistance 
Device  (VAD)  may  be  helpful  [1-5].  Recently  ECMO  has Eui Suk Chung, et al
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been adapted to the percutaneous approach and the self-charg-
ing  system,  so  that  it  can  support  the  whole  body  and  coro-
n a r y  c i r c u l a t i o n  f a s t ,  a n d  h a s  s h o w n  g o o d  c l i n i c a l  r e s u l t s  i n  
patients experiencing cardiogenic shock due to AMI [6-9]. On 
the  other  hand,  there  is  controversy  about  which  procedure 
should  be  first,  coronary  reperfusion  or  ECMO,  for  cardio-
genic  shock  due  to  AMI.  Therefore,  the  authors  have  re-
viewed  the  short-term  results  of  patients  who  had  received 
ECMO  just  before  coronary  reperfusion  in  cases  of  cardio-
genic  shock  due  to  AMI. 
MATERIALS AND METHODS
We  retrospectively  reviewed  20  cases  (median  age 
67.7±11.7,  male : female  13 : 7)  of  coronary  reperfusion  after 
application  of  EBS  (Capiox
Ⓡ  Emergency  Bypass  System 
[Terumo  Inc.,  Tokyo,  Japan])  due  to  postinfarct  cardiogenic 
shock  among  106  cases  of  ECMO  from  February  2005  to 
November 2009. We defined a state of cardiac arrest, systolic 
blood  pressure  below  70  mmHg  for  over  30  minutes  and 
clinical symptoms such  as oliguria, confusion, and ventricular 
tachycardia as cardiogenic shock. We applied ECMO to those 
patients  experiencing  cardiogenic  shock  and  performed  CPR 
in 14 of the cases (70%) (mean time 20.8±26.0 minutes).  In 
all  cases,  we  underwent  coronary  artery  bypass  under  the 
support  of  ECMO  and  chose  the  method  of  coronary  re-
perfusion  according  to  the  results.  After  using  ECMO  sup-
port,  arterial  pulse  wave  was  disappeared  in  14  cases,  and  in 
those  cases  we  additionally  inserted  an  IABP.  Immediately 
after coronary reperfusion, we started Aspirin and Clopidogrel 
in  all  patients.   
To  perform  ECMO,  we  inserted  a  17  Fr  cannula  into  the 
artery  and  21  Fr  cannula  into  the  vein  (Medtronic  Inc.
Ⓡ, 
DLP,  MN,  USA)  percutaneously  using  the  Seldinger  method 
and  adjusted  the  size  of  cannulae  according  to  the  patient’s 
body weight and body surface area. We infused with as much 
as  5,000  IU  heparin  before  cannulation,  and  maintained  an 
ACT  (Activated  Coagulation  Time)  in  the  range  of  180  to 
200  minutes.  We  maintained  cardiopulmonary  circulatory 
blood flow in the range of 3.0∼3.5 L/min/m
2 and stopped or 
lowered the vasopressor to the minimum dosage after ECMO 
support.  During  ECMO  support,  we  performed  echocardiog-
raphy daily to check heart function and to check for any ven-
tricular dilation or ventricular thrombus. We maintained plate-
let  and  hemoglobin  counts  over  50,000/μ and  10.0  gm/dL, 
respectively. During ECMO support, we employed continuous 
renal  replacement  therapy  (CRRT)  in  cases  of  acute  renal 
failure (ARF) by connecting CRRT unit to the ECMO circuit 
directly. 
The  weaning  from  ECMO  was  begun  after  the  initial  48 
hours from the application, raising the dosage of vasopressors 
and decreasing supportive circulatory blood flow. After wean-
ing  from  ECMO,  the  cannula  insertion  sites  were  sutured  af-
ter identification  of the femoral artery intima  in the Intensive 
Care  Unit  (ICU),  and  there  were  no  complications  from  the 
cannula  insertion  site  sutures. 
We  analyzed  the  risk  factors  using  a  2×2×2  K  Pearson's 
chi-square  test  and  Fisher’s  exact  test.  We  compared  the 
mean  values  of  the  clinical  results  using  a  nonparametric 
Mann-Whitney  U-test. 
RESULTS
The  mean  cannular  insertion  time  for  ECMO  application 
was  17.2±9.4  minutes,  we  performed  peripheral  circulation  at 
t h e  s a m e  t i m e  t o  p r e v e n t  l o w e r  e x t r e m i t y  f r o m  n e c r o s i s  i n  
two cases. The cannular insertions were performed in the cor-
onary  catheterization  room  in  most  cases  (17  cases).  Two 
cannular  insertions  were  performed  in  the  Emergency  Room 
and  one  in  the  ICU.
Coronary angiography showed 11 cases of three-vessel dis-
eases, 6 cases of two-vessel diseases, one case of single coro-
nary  disease  and  6  cases  of  left  main  branch  lesions.  The 
main  lesion  was  the  left  main  branch  in  5  cases,  the  left  an-
terior  descending  artery  in  4,  the  left  circumflex  artery  in  6, 
and  the  right  coronary  artery  in  5  cases.  We  decided  the 
method  of  coronary  reperfusion  according  to  each  patient’s 
coronary  angiography  results  and  state.  We  performed  13 
cases  of  coronary  bypass  graft  surgery  and  7  cases  of 
Percutaneous  Coronary  Intervent i o n  ( P C I ) .  T h e r e  w e r e  s u r g e -
ries  combined  with  coronary  bypass  graft  surgery  in  5  cases 
(mitral valvuloplasty in 2 cases, repair of a left ventricle rup-
ture  in  one  case,  Dor  procedure  in  one  case,  and  repair  of 
postinfarct  ventricular  septal  defect  in  one  case). Results of ECMO Support before Coronary Reperfusion in Cardiogenic Shock with AMI
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Table 1. Clinical results
Total Survivors  (n=10) Death  (n=10) p-value
ECMO  support  (hrs)
ICU  stay  (days)*
Admission  duration  (days)
  3 . 8 ±4.3
11.05±6.8
  28.75±31.1
 2 . 1 ±1.4
14.8±6.2
  50.1±31.6
5.6±5.4
7.3±5.4
7.4±5.3
0.06
0.00
0.01
*ICU=Intensive  care  unit.
Table 2. Pre ECMO risk factors
Variable
Weaning
(n=14)
Failure
(n=6)
p-value
(OR
††)
Survivors
(n=10)
Deaths
(n=10)
p-value
(OR)
Age  (＞70)
Sex  (female)
DM*
Hypertension
Renal  failure  (Creatinine＞1.6)
Culprit  lesion  (It)
Left  main  disease
3  vessel  disease
IABP  support
†
CPR
‡
CPR  time  (20＜ min)
Cannula  insertion  time  (＜15  min)
Reperfusion  (operation)
Ejection  fraction  (＜30%)
Hematocrit  (＜30%)
CRP  (0.5  mg/L＞)
∥
WBC  (＞10,000)
PH  (＜7.3)
AST  (＞100  U/L)
¶
ALT  (＞100  U/L)
#
NT  proBNP  (＞500  pg/mL)
§
Albumin  (＜3.0  g/dL)
Troponin  I  (＞10  ng/mL)
CKMB  (＞10  ng/mL)**
11
 5
 6
 5
 4
 4
 7
11
 9
 4
 8
 8
 5
 2
 4
10
 6
 6
 2
 8
 5
 3
 5
3
2
3
2
1
2
3
3
5
4
1
5
4
3
3
5
2
2
2
4
5
2
4
0.30
1.00
1.00
0.66
1.00
1.00
1.00
0.30
0.61
0.16
0.16
0.36
0.14
0.13
0.61
1.00
1.00
1.00
0.55
0.26
0.14
0.61
0.33
5
7
3
4
4
7
3
4
7
5
1
5
6
2
2
2
7
4
5
2
5
2
2
4
7
7
4
5
3
8
3
6
7
9
7
4
7
7
3
5
8
4
3
2
7
8
3
5
0.65
1.00
1.00
0.50
1.00
1.00
1.00
  0.656
1.00
0.14
0.02  (21.0)
1.00
1.00
0.02  (14.0)
1.00
0.35
1.00
1.00
0.65
1.00
0.29
0.01  (16.0)
1.00
1.00
*=Diabetes  mellitus; 
†=Cardiopulmonary  resuscitation; 
‡=Intra  aortic  balloon  pump; 
§=N-Terminal  fragment  of  the  prohormone, 
Brain-Type  natriuretic  peptide; 
∥=C  reactive  peptide; 
¶=Aspartate  aminotransferase; 
#=Alanine  aminotransferase;  **=Creatin  kinase 
MB; 
††=Odd  ratio.
 M e a n  E C M O  s u p p o r t  t i m e  w a s  3 . 8 ±4.3  days  (0.5  to  19.2 
days).  Fourteen  cases  (70%)  were  weaned  from  ECMO  and 
10  patients  (50%)  were  alive  and  discharged  from  the 
hospital.  The  mean  length  of  hospitalization  was  28.8±31.1 
d a y s  ( 1  t o  5 8  d a y s )  a n d  m e a n  t i m e  i n  I C U  w a s  1 1 . 1 ±6.8 
days  (1  to  25  days)  (Table  1).
The  cause  of  death  was  failure  of  ECMO  weaning  in  6 
cases, brain injury in 2 cases, restenosis of coronary artery in 
one  case,  and  sepsis  in  one  case.  The  causes  of  ECMO 
weaning failure were failure of left ventricular decompression 
in  2  cases,  decrease  of  circulatory  blood  flow  due  to  bleed-
ing,  and  sepsis  in  3  cases  and  heart  dysfunction  before 
ECMO  support  in  one  case.  The  main  complications  were 
sepsis and Disseminated Intravascular Coagulation (DIC) in 9 
cases, acute renal failure in 9 cases, bleeding in 8 cases, and 
brain injury in 4 cases. We applied CRRT to 8 of the 9 cas-Eui Suk Chung, et al
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Table 3. Risk factors during ECMO
Variable
Weaning 
(n=14)
Failure 
(n=6)
p-value  (OR
¶)
Survivors 
(n=10)
Deaths 
(n=10)
p-value  (OR)
Hematocrit  (＜26%)
Platelet  count  (＜100,000)
Albumin  (＜2.5  g/dL)
PH  (＜7.3)
AST  (＞400  U/L)*
ALT  (＞100  U/L)
†
ARF
‡
CKMB  (＞100)
§
Troponin  I  (＞100)
DIC
∥
Bleeding
Sepsis
ECMO  support  time  (＞4.5  days)
7
4
6
6
4
5
4
8
7
2
3
2
3
5
4
5
4
4
4
6
5
5
6
5
2
3
0.33
0.16
0.16
0.33
0.16
0.33
0.01
0.35
0.33
0.00  (5.00)
  0.02  (18.33)
0.55
0.30
4
3
3
4
2
4
1
4
3
1
1
0
0
8
5
8
6
6
5
9
9
9
7
7
4
6
0.17
0.65
0.07
0.65
0.17
1.00
0.00  (81.00)
0.06
0.02  (13.50)
0.02  (21.00)
0.02  (21.00)
0.09
0.01
*=Aspartate  aminotransferase; 
†=Alanine  aminotransferase; 
‡=Incase  creatininin  over  50%  of  normal  range; 
§=Creatin  Kinase; 
∥=Disseminated  intravascular; 
¶=Odd  ratio.
es of ARF. The surviving patients received follow-up care for 
a  mean  of  476.6±374.6  days  (27  to  1,318  days).  There  were 
no  deaths  after  discharge.  The  mean  left  ventricular  ejection 
fraction after discharge was 44.4±16.0% (14.5 to 63.1%), and 
all  patients  were  considered  to  be  in  New  York  Heart 
Association  functional  class  (NYHA  Fc)  I  or  II.
We analyzed the risk factors related to death before ECMO 
and  after  ECMO.  CPR  time  before  ECMO  (＞20  min),  left 
ventricular ejection fraction (＜40%) before ECMO, and con-
centration of albumin (＜3.0 g/dL) were related to death (p＜ 
0.05). ECMO support time (＞4.5 days), increase of Troponin 
I (＞100 ng/mL), ARF, DIC, and complications such as blee-
ding  were  also  related  to  the  death  (p＜0.05,  Table  2,  3).   
DISCUSSION
Circulatory  supporting  devices  such  as  IABP  and  VAD 
limit  the  effect  of  cardiogenic  shock  due  to  AMI.  IABP  is 
fast  and  easy  to  apply  and  increases  coronary  blood  flow. 
However,  its  effectiveness  could  be  reduced  in  cases  of  car-
diac  arrest  or  ventricular  arrhythmia  [1,2].  VAD  can  also  be 
effective,  but  requires  an  additional  surgical  procedure,  more 
time,  and  money,  and  is  therefore  unsuitable  in  case  of  an 
emergency.  Recently,  VAD  that  can  be  applied  percuta-
neously has become available. However, additional equipment 
and  procedures  are  required  in  order  to  apply  a  VAD  [10].
Since  the  advent  of  the  percutaneous  approach  for  ECMO, 
it has shown good results and that it can be applied relatively 
quickly.  Its  usage  has  become  popular.  CPR  with  ECMO 
shows  better  results  than  CPR  alone,  especially  in  cases  of 
cardiogenic  shock.  In  2008,  Chen  et  al.  reported  that  CPR 
with ECMO obtained better results than CPR without ECMO 
when CPR was required over than 10 minutes. Prodhan et al. 
reported  similar  results  [11,12].
There  has  been  debate  about  whether  coronary  reperfusion 
or  ECMO  support  should  be  first  applied  first  at  the  time  of 
postinfarct  cardiogenic  shock.  In  most  cases,  there  has  been 
limited application of ECMO after medical treatment and cor-
onary  reperfusion  with  IABP  support  at  the  time  of  cardio-
genic  shock  due  to  AMI  [13].  However,  in  the  high  risk 
group,  maintaining  coronary  and  whole  body  circulation 
through  aggressive  cardiopulmon a r y  c i r c u l a t o r y  s u p p o r t  i s  
helpful  in  advance.   
In  2005,  Burkle  et  al.  reported  that  the  results  of  coronary 
reperfusion after ECMO support showed a better prognosis in 
high  risk  patients  who  had  ischemic  heart  disease  [14].  In 
2007,  Vanier  et  al.  reported  that  the  weaning  rate  from 
ECMO  and  the  survival  rate  were  100%  and  80%,  re-
spectively, in patients who underwent coronary reperfusion af-
ter ECMO support [15]. In Korea, Rhee et al. [7] and Ryu et Results of ECMO Support before Coronary Reperfusion in Cardiogenic Shock with AMI
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al. [8] reported the results of ECMO support before and after 
coronary reperfusion in ischemic heart disease, however, there 
has  been  no  report  of  ECMO  support  just  before  coronary 
reperfusion.  In this study, we performed ECMO on high risk 
patients  who  had  cardiogenic  shock  and  identified  an  ECMO 
weaning rate of 70% and a survival rate of 50%, which were 
similar  results  to  those  of  several  previous  studies. 
There have been varied results in the weaning and survival 
rates  after  ECMO  support.  Rastan  et  al.  reported  a  63.3% 
w e a n i n g  r a t e  a n d  a  2 4 . 8 %  s u r v i v a l  r a t e  a f t e r  E C M O  s u p p o r t  
in  their  study  of  517  cases  in  2010,  and  Bakhtiary  et  al.  re-
p o r t e d  a  5 6 %  w e a n i n g  r a t e  a n d  a  3 3 %  s u r v i v a l  r a t e  i n  4 5  
cases  in  2008.  There  have  been  studies  with  weaning  rates 
ranging  from  40%  to  100%  and  survival  rates  ranging  from 
25%  to  80%  [16-18].  It  is  necessary  to  analyze  the  risk  fac-
tors and to reduce them in order to improve the rates of sur-
vival  and  ECMO  weaning.  Rastan  et  al.  addressed  these 
rates’ relationships with age, DM, hepatic failure, Euro score, 
ARF, and lactate and cardiac enzyme elevation [16]. Zhang et 
al.  reported  a  noticeable  elevation  of  cardiac  enzyme,  in 
weaning  failure group [19]. Bakhtiary  et al.  suggested a rela-
tionship  with  lactate  concentration,  pulmonary  arterial  hyper-
tension,  DM,  and  IABP  between  waning  group  and  weaning 
failure  group  [17].  Recently  Chen  et  al.  claimed  that  CPR 
time  was  closely  related  with  the  results  of  ECMO  support 
[11].  This  study  identified  that  CPR  time  before  ECMO  sup-
po rt,,  w hich con sistent w ith  th e arg umen t o f Ch en et al. , and  
left  ventricular  ejection  fraction  before  ECMO  support  had 
significant  relationship  with  successful  weaning  from  ECMO. 
We  therefore  think  that  early  ECMO  application  should  be 
considered  in  high  risk  patients  who  have  reduced  cardiac 
function.  Analysis  of  cardiac  enzyme  showed  results  similar 
to those reported by Rastan and Zhang et al. Troponin I lev-
els had statistical significance, whereas CKMB levels did not. 
Continuous  monitoring  of  elevated  cardiac  enzymes  may  re-
veal their relationship to the death rate during or after ECMO 
support.  Previous  studies  have  reported  that  complications 
such  as  bleeding  during  ECMO  support,  multiple  organ  fail-
ure,  and  ARF  may  contribute  to  an  increased  death  rate 
[7,8,20].  In  this  study,  such  complications  contributed  to  an 
increased death rate as well. Decreasing the incidence of ma-
jor  complications  would  be  helpful  in  improving  the  survival 
rate in the future. Nevertheless, factors such as the site of the 
coronary  artery  lesion,  the  method  of  coronary  reperfusion, 
three-vessel  diseases,  and  the  existence  of  a  left  main  branch 
lesion did not influence the survival rate. We additionally in-
serted  IABP  in  the  14  cases  which  had  lost  arterial  pulse 
waves,  but  there  was  no  meaningful  difference  in  survival 
rates  between  the  group  with  IABP  and  the  group  without 
IABP. Nevertheless, ECMO support with IABP could help to 
raise survival rates by recovering the arterial wave, decreasing 
afterload,  increasing  coronary  blood  flow,  and  weaning 
ECMO  support  [17]  as  has  been  reported  by  Bakhtiary  et  al. 
[17].  IABP  should  be  applied  during  ECMO  support  if  there 
is  no  contraindication  to  it. 
Short  term  results  are  usually  satisfactory  after  discharge. 
Studies have reported no differences in survival rates between 
immediately following discharge and one year after discharge. 
This  study  also  showed  no  deaths  immediately  after  dis-
charge,  and  a  good  clinical  course  in  all  cases  [11,20].
CONCLUSION
In  this  study,  we  analyzed  the  short-term  results  and  risk 
factors related to death when ECMO support was applied be-
fore  coronary  reperfusion  therapy  in  cases  of  postinfarct  car-
diogenic  shock.  Study  limitations  include  a  small  study 
group,  retrospective  study,  and  the  possibility  of  selection 
bias  from  nonrandomized  study  design.  Coronary  reperfusion 
therapy  after  ECMO  support  showed  clinically  significant  re-
sults  and  good  short-term  results  after  discharge.  In  the  high 
r i s k  g r o u p ,  e a r l y  E C M O  s u p p o r t  b efore  coronary  reperfusion 
procedures,  correction  of  risk  factors,  and  minimization  of 
complications  would  result  in  improved  clinical  results  for 
cardiogenic  shock  due  to  AMI.  Long-term  clinical  applica-
tions  of  ECMO  require  further  study. 
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